Predictors of Early Discontinuation of Interferon-Free Direct Antiviral Agents in Patients With HCV and Advanced Fibrosis: Results of A Real-Life Cohort

OBJECTIVES: To determinate risk factors for premature treatment discontinuation among patients infected with HCV with advanced fibrosis treated with IFN-free direct antiviral agents (DAA)-based therapy. METHODS: We included all patients with chronic HCV infection and advanced fibrosis who initiated...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-10, Vol.20 (9), p.A926-A927
Main Authors: Miotto, N, Mendes, LC, Zanaga, LP, Goncales, ES, Lazarini, MS, Pedro, MN, Goncales Jr, FL, Stucchi, RS, Vigani, AG
Format: Article
Language:English
Subjects:
Age
Antiviral agents
Antiviral drugs
Chronic illnesses
Chronic infection
Cirrhosis
Cohort analysis
Comorbidity
Cystic fibrosis
Determinate
Discontinued
Fibrosis
Hemoglobin
Hepatitis C
Infections
Interferon
Liver cirrhosis
Liver diseases
Medical records
Medical treatment
Multivariate analysis
Patients
Questionnaires
Ribavirin
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES: To determinate risk factors for premature treatment discontinuation among patients infected with HCV with advanced fibrosis treated with IFN-free direct antiviral agents (DAA)-based therapy. METHODS: We included all patients with chronic HCV infection and advanced fibrosis who initiated treatment with IFN-free DAA therapy at an university hospital from December 2015 through June 2016. We prospectively collected data from medical records using standardized questionnaires and evaluated them using Epilnfo 7.1.2.0. Primary outcome was treatment interruption and factors associated. RESULTS: Of total, 214 patients were included in this study, 180 patients treated with sofosbuvir(SOF) + daclatasvir ± ribavirin(RBV), 31 received SOF + simeprevir ± RBV, and 3 treated with SOF+RBV Treatment discontinuation rate was 8.9% (19), and cirrhotic decompensation was the main reason (8; 42.1%). Among patients with Child B or C cirrhosis (31), 10 (32.2%) prematurely interrupted treatment. Risk factors for treatment discontinuation in univariate analysis were higher age (p 0.0252), higher comorbidity index (p 0.0078), higher Model for end stage liver disease (MELD) (p
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2017.08.3091